<?xml version="1.0" encoding="UTF-8"?>
<p>The prognostic value of CD151 was previously emphasized in low-grade prostate cancer, in which CD151 expression could predict the clinical outcome of patients more accurately than the traditional histological grading method (
 <xref rid="B1" ref-type="bibr">Ang et al., 2004</xref>). Given the strong association between CD151 and lung cancer (
 <xref rid="B81" ref-type="bibr">Tokuhara et al., 2001</xref>; 
 <xref rid="B44" ref-type="bibr">Kwon et al., 2013</xref>), especially adenocarcinoma which is the most common NSCLC subtype, CD151 expression has proven to be especially informative on patient prognosis. Furthermore, the prognostic utility of CD151 expression may be extended to other diseases such as asthma, in which the expression of CD151 was associated with disease severity (
 <xref rid="B59" ref-type="bibr">Qiao et al., 2017</xref>).
</p>
